摘要
目的定量分析转化生长因子受体2(Transforming growth factor receptor 2,TGFβR2)在非小细胞肺癌(non-small cell lung cancer,NSCLC)及其癌旁组织中的表达,探讨TGFβR2的表达在NSCLC伴随诊断(companion diagnostic,CD)中的意义。方法取患者手术中立即取材置于液氮中的新鲜组织标本(90例NSCLC组织,40例癌旁肺组织),抽提RNA,采用实时荧光定量PCR(RT-q PCR)技术检测标本。TGFβR2基因表达量通过2-ΔΔCT方法计算。TGFβR2的表达用(x±s)呈现。独立样本t检验比较两组差异,应用Kaplan-Meier生存分析来评估总生存期(Overall survival,OS)和无进展生存期(Progression-free survival,PFS)。结果实验结果表明NSCLC组织中TG FβR2的表达(3.19±4.28)显著高于癌旁肺组织(1.01±0.41),二者差异具有统计学意义。生存分析显示TG FβR2高表达的NSCLC患者预后不良,总生存期和无进展生存期明显降低。结论 TG FβR2可以作为NSCLC潜在的伴随诊断分子标志物。
Objective To determine the expression levels of transforming growth factor receptor 2（ TGFβR2） in non-small cell lung cancer（ NSCLC） and its significance. Methods Total RNA was extracted from NSCLC tissue（ n = 90） and adjacent non-cancerous tissue（ n = 40）, Real-Time quantitative PCR was performed. The 2- ΔΔCTmethod was used to quantify the expression levels of TG FβR2. Independent t-test was performed to examine differences between two groups,Kaplan-M eier curves were used to determine overall survival（ OS） and progression-free survival（ PFS） of patients.Results TG FβR2 expression in NSCLC tissue was significantly higher than that in adjacent noncancerous tissue（ 3. 19 ± 4. 28 vs 1. 01 ± 0. 41,P〈0. 05）. Kaplan-M eier survival analysis demonstrated that prognosis was worse in patients with high expression of TG FβR2. Expression of TG FβR2 was significantly associated with decreased OS and PFS in NSCLC patients. Conclusion TG FβR2 might be used as a bio-marker for companion diagnostics of non-small cell lung cancer.
出处
《同济大学学报（医学版）》
CAS
2015年第6期19-23,共5页
Journal of Tongji University(Medical Science)
基金
国家自然科学基金(81371595)
